Adicet Bio, Inc. (ACET)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch ACET
See up to 3 months of ACET. The 7-day demo opens the 1M and 3M ranges and puts ACET on your watchlist.
Start 7-day demoLatest ACET insider trades
About Adicet Bio, Inc. (ACET)
The SEC lists Adicet Bio, Inc. under CIK 0001720580, in pharmaceutical preparations. It is grouped with Health Care companies on this site.
ACET Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 1 | 18,300 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ACET insider transactions (Form 4)
3123 Form 4 filings on record, the earliest from Jun 11, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Lloyd Klickstein - Officer | Grant or award | Stock Option (Right to Buy) | 18,300 | $0.00 | - | |
| Chen Schor - Officer | Grant or award | Stock Option (Right to Buy) | 55,000 | $0.00 | - | |
 Blake Aftab - Officer | Grant or award | Stock Option (Right to Buy) | 55,000 | $0.00 | - | |
| Steve Dubin | Grant or award | Stock Option (Right to Buy) | 4,200 | $0.00 | - | |
 Jeffrey Chodakewitz | Grant or award | Stock Option (Right to Buy) | 4,200 | $0.00 | - | |
| Michael Grissinger | Grant or award | Stock Option (Right to Buy) | 4,200 | $0.00 | - | |
| Andrew Sinclair | Grant or award | Stock Option (Right to Buy) | 4,200 | $0.00 | - | |
| Katie Peng | Grant or award | Stock Option (Right to Buy) | 4,200 | $0.00 | - | |
| Lloyd Klickstein | Grant or award | Stock Option (Right to Buy) | 4,200 | $0.00 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Common Stock | 250,000 | - footnote F1 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Pre-Funded Warrant (Right to Buy) | 250,000 | - footnote F1 | - | |
| ||||||
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 74,577 | $7.04 footnote F1 | $525K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 74,268 | $7.21 footnote F4 | $535K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 74,751 | $7.27 footnote F5 | $543K | |
| ||||||
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 29,319 | $6.53 | $191K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 2,400 | $6.38 | $15K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 32,523 | $6.29 | $205K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 40,416 | $6.52 | $264K | |
| Brian Nicholas Harvey - Officer | Grant or award | Stock Option (Right to Buy) | 43,361 | $0.00 | - | |
| Chen Schor - Officer | Grant or award | Stock Option (Right to Buy) | 468,555 | $0.00 | - | |
| Julia D. Maltzman - Officer | Grant or award | Stock Option (Right to Buy) | 72,555 | $0.00 | - | |
| Don Healey - Officer | Grant or award | Stock Option (Right to Buy) | 43,361 | $0.00 | - | |
| Blake Aftab - Officer | Grant or award | Stock Option (Right to Buy) | 72,555 | $0.00 | - | |
| Blake Aftab - Officer | Tax withholding / forfeiture | Common Stock | 535 | $8.44 | $5K | |
| Don Healey - Officer | Tax withholding / forfeiture | Common Stock | 535 | $8.44 | $5K | |
| Chen Schor - Officer | Tax withholding / forfeiture | Common Stock | 1,755 | $8.44 | $15K | |
| Brian Nicholas Harvey - Officer | Tax withholding / forfeiture | Common Stock | 546 | $8.44 | $5K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market purchase | Common Stock | 1,500,000 footnote F1 | $1.00 | $1.50M | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market purchase | Common Stock | 3,500,000 footnote F1 | $1.00 | $3.50M | |
| ||||||
| Steve Dubin | Grant or award | Common Stock | 5,900 | $0.00 | - | |
| Steve Dubin | Grant or award | Stock Option (Right to Buy) | 26,400 | $0.00 | - | |
Item 7.01, 8.01, 9.01
Item 7.01, 9.01
Item 7.01, 9.01
Item 2.02, 9.01
ACET insider trading FAQ
What is the latest insider trade for ACET?
Adicet Bio, Inc. (ACET) had 1 insider filing in the last 90 days, with the most recent on 2026-08-07. The full record for ACET runs to 23 Form 4 filings, the earliest from 2025-06-11. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ACET stock?
No insider purchases of ACET were filed in the last 90 days. 5 purchases are on record for this company.
How many insiders are selling ACET stock?
No insider sales of ACET were filed in the last 90 days. 4 sales are on record for this company.
Where can I see ACET SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ACET Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Lloyd Klickstein view on EDGAR
- - Chen Schor view on EDGAR
- - Blake Aftab view on EDGAR
- - Steve Dubin view on EDGAR
- - Jeffrey Chodakewitz view on EDGAR
- - Michael Grissinger view on EDGAR
- - Andrew Sinclair view on EDGAR
- - Katie Peng view on EDGAR
- - Lloyd Klickstein view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where ACET's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ACET with a 7-day demo
- ACET on your watchlist
- Every ACET Form 4 filing on record
- Up to 3 months of ACET price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
